The perplexing paradox of paraquat: The case for host-based susceptibility and postulated neurodegenerative effects

Journal of Biochemical and Molecular Toxicology

Volumn 28, Issue 5, 2014, Pages 191-197

  Jones, Byron C ^a,b   Huang, Xuemei ^b   Mailman, Richard B ^b   Lu, Lu ^c,d   Williams, Robert W ^c  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d NANTONG UNIVERSITY   (China)

Author keywords

Complex Traits; Host Susceptibility; Iron, Neurodegeneration; Paraquat; Parkinson's Disease; Toxicogenetics

Indexed keywords

DOPAMINE TRANSPORTER; GLUTATHIONE TRANSFERASE T1; INSECTICIDE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PARAQUAT; PESTICIDE; HERBICIDE; POLLUTANT;

ARTICLE; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENETIC DIFFERENCE; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HOST SUSCEPTIBILITY; HUMAN; HYPERKINESIA; MITOCHONDRIAL TOXICITY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RURAL POPULATION; SUBSTANTIA NIGRA PARS COMPACTA; GENETIC PREDISPOSITION; GENETICS; NEUROTOXICITY SYNDROMES; POLLUTANT; TOXICITY;

ENVIRONMENTAL POLLUTANTS; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HERBICIDES; HUMANS; NEUROTOXICITY SYNDROMES; PARAQUAT;

EID: 84899949068     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.21552     Document Type: Article

References (66)

1. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010;68:270-281.
2. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol 2013;9:445-454.
3. Kieburtz K, Wunderle KB. Parkinson's disease: evidence for environmental risk factors. Mov Disord. 2013;28:8-13.
4. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012;72:893-901.
5. Miller GW. Paraquat: the red herring of Parkinson's disease research. Toxicol Sci 2007;100:1-2.
6. Cory-Slechta DA, Thiruchelvam M, Di Monte DA. Letter regarding: "Paraquat: the red herring of Parkinson's disease research". Toxicol Sci 2008;103:215-216.
7. LoPachin RM, Gavin T. Response to "Paraquat: the red herring of Parkinson's disease research." Toxicol Sci 2008;103:219-221.
8. Choi WS, Kruse SE, Palmiter RD, Xia Z. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci U S A 2008;105:15136-15141.
9. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28:57-87.
10. Gwinn-Hardy K. Genetics of parkinsonism. Mov Disord 2002;17:645-656.
11. Jones BC, Lu L, Williams RW, Unger EL, Yin L. Response to Breckenridge et al. Neurotoxicology 2013;38:23-24.
12. Kamel F, Boyes WK, Gladen BC, Rowland AS, Alavanja MC, Blair A, Sandler DP. Retinal degeneration in licensed pesticide applicators. Am J Ind Med 2000;37:618-628.
13. Kamel F, Tanner C, Umbach D, Hoppin J, Alavanja M, Blair A, Comyns K, Goldman S, Korell M, Langston J, Ross G, Sandler D. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am J Epidemiol 2007;165:364-374.
14. Kamel F, Umbach DM, Bedlack RS, Richards M, Watson M, Alavanja MC, Blair A, Hoppin JA, Schmidt S, Sandler DP. Pesticide exposure and amyotrophic lateral sclerosis. Neurotoxicology 2012;33:457-462.
15. Kamel F, Goldman SM, Umbach DM, Chen H, Richardson G, Barber MR, Meng C, Marras C, Korell M, Kasten M, Hoppin JA, Comyns K, Chade A, Blair A, Bhudhikanok GS, Webster RG, William LJ, Sandler DP, Tanner CM. Dietary fat intake, pesticide use, and Parkinson's disease. Parkinsonism Relat Disord 2014;20:82-87.
16. Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppin JA, Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, Sandler DP, Blair A, Langston JW, Tanner CM. Genetic modification of the association of paraquat and Parkinson's disease. Mov Disord 2012;27:1652-1658.
17. Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson's disease in rural California. Environ Health Perspect 2009;117:1912-1918.
18. Wang YS, Yen JH, Hsieh YN, Chen YL. Dissipation of 2, 4-D glyphosate and paraquat in river water. Water Air Soil Pollution 1994;72:1-4.
19. Fernandez M, Ibanez M, Pico Y, Manes J. Spatial and temporal trends of paraquat, diquat, and difenzoquat contamination in water from marsh areas of the Valencian community (Spain). Arch Environ Contam Toxicol 1998;35:377-384.
20. Hertzman C, Wiens M, Bowering D, Snow B, Calne D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am J Ind Med 1990;17:349-355.
21. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997;48:1583-1588.
22. Landrigan PJ, Sonawane B, Butler RN, Trasande L, Callan R, Droller D. Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect 2005;113:1230-1233.
23. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011;119:866-872.
24. Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol 2011;26:547-555.
25. McCormack AL, Atienza JG, Johnston LC, Andersen JK, Vu S, Di Monte DA. Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem 2005;93:1030-1037.
26. Elbaz A, Clavel J, Rathouz PJ, Moisan F, Galanaud JP, Delemotte B, Alperovitch A, Tzourio C. Professional exposure to pesticides and Parkinson disease. Ann Neurol 2009;66:494-504.
27. Firestone JA, Lundin JI, Powers KM, Smith-Weller T, Franklin GM, Swanson PD, Longstreth WT, Jr., Checkoway H. Occupational factors and risk of Parkinson's disease: a population-based case-control study. Am J Ind Med 2010;53:217-223.
28. Berry C, La VC, Nicotera P. Paraquat and Parkinson's disease. Cell Death Differ 2010;17:1115-1125.
29. Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppin JA, Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, Sandler DP, Blair A, Langston JW, Tanner CM. Genetic modification of the association of paraquat and Parkinson's disease. Mov Disord 2012;27:1652-1658.
30. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
31. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979;1:249-254.
32. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
33. Mailman RB, Huang X. Dopamine receptor pharmacology. In: Koller WC, Melamed E, editors. Parkinson's disease and related disorders, Part 1 . Amsterdam, The Netherlands: Elsevier; 2007. pp 77-105,
34. Jones BC, Miller DB, O'Callaghan JP, Lu L, Unger EL, Alam G, Williams RW. Systems analysis of genetic variation in MPTP neurotoxicity in mice. Neurotoxicology 2013;37:26-34.
35. Breckenridge CB, Sturgess NC, Butt M, Wolf JC, Zadory D, Beck M, Mathews JM, Tisdel MO, Minnema D, Travis KZ, Cook AR, Botham PA, Smith LL. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice. Neurotoxicology 2013;37:1-14.
36. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002;10:119-127.
37. Li X, Yin J, Cheng CM, Sun JL, Li Z, Wu YL. Paraquat induces selective dopaminergic nigrostriatal degeneration in aging C57BL/6 mice. Chin Med J (Engl) 2005;118:1357-1361.
38. Yin L, Lu L, Prasad K, Richfield EK, Unger EL, Xu J, Jones BC. Genetic-based, differential susceptibility to paraquat neurotoxicity in mice. Neurotoxicol Teratol 2011;33:415-421.
39. Jiao Y, Lu L, Williams RW, Smeyne RJ. Genetic dissection of strain dependent paraquat-induced neurodegeneration in the substantia nigra pars compacta. PLoS One 2012;7:e29447.
40. Peng J, Peng L, Stevenson FF, Doctrow SR, Andersen JK. Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson's disease accelerate age-related neurodegeneration. J Neurosci 2007;27:6914-6922.
41. Peng J, Stevenson FF, Oo ML, Andersen JK. Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation. Free Radic Biol Med 2009;46:312-320.
42. Rappold PM, Cui M, Chesser AS, Tibbett J, Grima JC, Duan L, Sen N, Javitch JA, Tieu K. Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc Natl Acad Sci USA 2011;108:20766-20771.
43. Rhodes SL, Ritz B. Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol Dis 2008;32:183-195.
44. Wu B, Song B, Tian S, Huo S, Cui C, Guo Y, Liu H. Central nervous system damage due to acute paraquat poisoning: a neuroimaging study with 3.0 T MRI. Neurotoxicology 2012;33:1330-1337.
45. Daugherty A, Raz N. Age-related differences in iron content of subcortical nuclei observed in vivo: a meta-analysis. Neuroimage 2013;70:113-121.
46. Hunter RL, Liu M, Choi DY, Cass WA, Bing G. Inflammation and age-related iron accumulation in F344 rats. Curr Aging Sci 2008;1:112-121.
47. Kaur D, Peng J, Chinta SJ, Rajagopalan S, Di Monte DA, Cherny RA, Andersen JK. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging 2007;28:907-913.
48. Du G, Lewis MM, Sen S, Wang J, Shaffer ML, Styner M, Yang QX, Huang X. Imaging nigral pathology and clinical progression in Parkinson's disease. Mov Disord 2012;27:1636-1643.
49. Double KL, Todd G, Duma SR. Pathophysiology of transcranial sonography signal changes in the human substantia nigra. Int Rev Neurobiol 2010;90:107-120.
50. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB. Selective increase of iron in substantia nigra zona compacta of Parkinsonian brains. J Neurochem 1991;56:978-982.
51. Ritz BR, Manthripragada AD, Costello S, Lincoln SJ, Farrer MJ, Cockburn M, Bronstein J. Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ Health Perspect 2009;117:964-969.
52. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dork T, Schurmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomaki K, von SK, Blomqvist C, Mannermaa A, Uusitupa M, Eskelinen M, Tengstrom M, Kosma VM, Kataja V, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Devilee P, van Asperen CJ, Jacobi CE, Tollenaar RA, Huijts PE, Klijn JG, Chang-Claude J, Kropp S, Slanger T, Flesch-Janys D, Mutschelknauss E, Salazar R, Wang-Gohrke S, Couch F, Goode EL, Olson JE, Vachon C, Fredericksen ZS, Giles GG, Baglietto L, Severi G, Hopper JL, English DR, Southey MC, Haiman CA, Henderson BE, Kolonel LN, Le ML, Stram DO, Hunter DJ, Hankinson SE, Cox DG, Tamimi R, Kraft P, Sherman ME, Chanock SJ, Lissowska J, Brinton LA, Peplonska B, Klijn JG, Hooning MJ, Meijers-Heijboer H, Collee JM, van den Ouweland A, Uitterlinden AG, Liu J, Lin LY, Yuqing L, Humphreys K, Czene K, Cox A, Balasubramanian SP, Cross SS, Reed MW, Blows F, Driver K, Dunning A, Tyrer J, Ponder BA, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gabrieau V, Sigurdson A, Doody M, Struewing JP, Alexander B, Easton DF, Pharoah PD. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008;4:e1000054.
53. Ermann J, Glimcher LH. After GWAS: mice to the rescue? Curr Opin Immunol 2012;24:564-570.
54. Chan LL, Rumpel H, Yap K, Lee E, Loo HV, Ho GL, Fook-Chong S, Yuen Y, Tan EK. Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:1383-1386.
55. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008;70:1411-1417.
56. Vaillancourt DE, Spraker MB, Prodoehl J, Abraham I, Corcos DM, Zhou XJ, Comella CL, Little DM. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378-1384.
57. Peran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Demonet JF, Stefani A, Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133:3423-3433.
58. Du G, Lewis MM, Styner M, Shaffer ML, Sen S, Yang QX, Huang X. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 2011;26:1627-1632.
59. Boska MD, Hasan KM, Kibuule D, Banerjee R, McIntyre E, Nelson JA, Hahn T, Gendelman HE, Mosley RL. Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis 2007;26:590-596.
60. Du G, Lewis MM, Sterling NW, Kong L, Chen H, Mailman RB, Huang X. Microstructural changes in the substantia nigra of asymptomatic agriculture workers. Neurobehav Tox Teratol 2014;41:60-64.
61. Connor JR. Iron transport proteins in the diseased brain. J Neurol Sci 2003;207:112-113.
62. Connor JR. Iron acquisition and expression of iron regulatory proteins in the developing brain: manipulation by ethanol exposure, iron deprivation and cellular dysfunction. Dev Neurosci 1994;16:233-247.
63. Connor JR, Benkovic SA. Iron regulation in the brain: histochemical, biochemical, and molecular considerations. Ann Neurol 1992;32(Suppl):S51-S61.
64. Liu Y, Connor JR. Iron and ER stress in neurodegenerative disease. Biometals 2012;25:837-845.
65. Snyder AM, Connor JR. Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 2009;1790:606-614.
66. Tandara L, Salamunic I. Iron metabolism: current facts and future directions. Biochem Med (Zagreb) 2012;22:311-328.